Skip to content

Neos Therapeutics, Inc.

Delisted

CIK 1467652fmd_0HBY456BTB240AA1M5ZG06GKKWManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2013 to Sep 30, 2020, 28 periods

Latest annual · FY2019

Millions
Total revenues
65
Gross profit
40
Operating income
(10)
Net income
(17)
Free cash flow
(12)

Latest quarter · Q3 FY2020

Millions
Total revenues
13
Gross profit
7
Operating income
(3)
Net income
(5)
Free cash flow
(2)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2016 to FY2019
+86.1%
Revenue, 5 yearsFY2014 to FY2019
+143.3%
Net income, 5 yearsFY2014 to FY2019
n/m

Neos Therapeutics, Inc. financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2019FY2018ChangeSource
Revenue$64.6 million$50 million+29.3%10-K 2020-03-13 · proof
Gross profit$39.5 million$23.1 million+71.4%10-K 2020-03-13 · proof
Operating income-$10.4 million-$43.5 million10-K 2020-03-13 · proof
Net income-$16.9 million-$51.7 million10-K 2020-03-13 · proof
Cash from operating activities-$10.8 million-$41.4 million10-K 2020-03-13 · proof
Free cash flow-$11.9 million-$42.8 million10-K 2020-03-13 · proof
Total assets$90.9 million$111.4 million-18.4%10-K 2020-03-13 · proof
Total liabilities$97 million$103.5 million-6.3%10-K 2020-03-13 · proof
Cash and cash equivalents$16.8 million$46.5 million-63.8%10-K 2020-03-13 · proof
Total debt$44.9 million$51.8 million-13.2%10-Q 2020-11-09 · proof
What was Neos Therapeutics, Inc.'s revenue in fiscal 2019?
Neos Therapeutics, Inc. reported revenue of $64.6 million for fiscal 2019 (the year ended Dec 31, 2019), against $50 million the year before (+29.3%). Source: the 10-K filed with the SEC on Mar 13, 2020. SEC
What was Neos Therapeutics, Inc.'s gross profit in fiscal 2019?
Neos Therapeutics, Inc. reported gross profit of $39.5 million for fiscal 2019 (the year ended Dec 31, 2019), against $23.1 million the year before (+71.4%). Source: the 10-K filed with the SEC on Mar 13, 2020. SEC
What was Neos Therapeutics, Inc.'s operating income in fiscal 2019?
Neos Therapeutics, Inc. reported operating income of -$10.4 million for fiscal 2019 (the year ended Dec 31, 2019), against -$43.5 million the year before. Source: the 10-K filed with the SEC on Mar 13, 2020. SEC
What was Neos Therapeutics, Inc.'s net income in fiscal 2019?
Neos Therapeutics, Inc. reported net income of -$16.9 million for fiscal 2019 (the year ended Dec 31, 2019), against -$51.7 million the year before. Source: the 10-K filed with the SEC on Mar 13, 2020. SEC
What was Neos Therapeutics, Inc.'s cash from operating activities in fiscal 2019?
Neos Therapeutics, Inc. reported cash from operating activities of -$10.8 million for fiscal 2019 (the year ended Dec 31, 2019), against -$41.4 million the year before. Source: the 10-K filed with the SEC on Mar 13, 2020. SEC
What was Neos Therapeutics, Inc.'s free cash flow in fiscal 2019?
Neos Therapeutics, Inc. reported free cash flow of -$11.9 million for fiscal 2019 (the year ended Dec 31, 2019), against -$42.8 million the year before. Source: the 10-K filed with the SEC on Mar 13, 2020. SEC
What are Neos Therapeutics, Inc.'s total assets?
As of Dec 31, 2019, Neos Therapeutics, Inc. reported total assets of $90.9 million, against $111.4 million a year earlier (-18.4%). Source: the 10-K filed with the SEC on Mar 13, 2020. SEC
What are Neos Therapeutics, Inc.'s total liabilities?
As of Dec 31, 2019, Neos Therapeutics, Inc. reported total liabilities of $97 million, against $103.5 million a year earlier (-6.3%). Source: the 10-K filed with the SEC on Mar 13, 2020. SEC
What are Neos Therapeutics, Inc.'s cash and cash equivalents?
As of Dec 31, 2019, Neos Therapeutics, Inc. reported cash and cash equivalents of $16.8 million, against $46.5 million a year earlier (-63.8%). Source: the 10-K filed with the SEC on Mar 13, 2020. SEC
What is Neos Therapeutics, Inc.'s total debt?
As of Dec 31, 2019, Neos Therapeutics, Inc. reported total debt of $44.9 million, against $51.8 million a year earlier (-13.2%). Source: the 10-Q filed with the SEC on Nov 9, 2020. SEC

Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1467652&period_type=annual&limit=5"

Information only, not investment advice.